Low abundance of circulating tumor DNA in localized prostate cancer [article]

S. Tom Hennigan, Shana Y. Trostel, Nicholas T. Terrigino, Olga S. Voznesensky, Rachel J. Schaeffer, Nichelle C. Whitlock, Scott Wilkinson, Nicole V. Carrabba, Rayann Atway, Steven Shema, Ross Lake, Amalia R. Sweet (+8 others)
2019 bioRxiv   pre-print
Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies for detection of clinically significant disease prior to treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely to harbor aggressive disease. We applied ultra-low pass whole genome sequencing to profile cell-free DNA from 112 patients diagnosed with localized prostate cancer,
more » ... d performed targeted resequencing of plasma DNA for somatic mutations previously identified in matched solid tumor in nine cases. We also performed similar analyses on patients with metastatic prostate cancer. In all cases of localized disease, even in clinically high-risk patients who subsequently recurred, we did not detect ctDNA by either method in plasma acquired before surgery or before recurrence. In contrast, ctDNA was detected from patients with metastatic disease. Our findings demonstrate clear differences between localized and advanced prostate cancer with respect to the dissemination and detectability of ctDNA. Because allele-specific alterations in ctDNA are below the threshold for detection in localized prostate cancer, other approaches to identify cell-free nucleic acids of tumor origin may demonstrate better specificity for aggressive disease.
doi:10.1101/655506 fatcat:byum2hdwbfbnjaywrejrdmronq